Molecular Diagnostics: The Shift to Complexity. Molecular Diagnostics Regulation: Where do we go from here? David W Feigal, Jr.

Similar documents
The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

The Intersection of Genomics Research and the IDE Regulation

Overview of the FDA Approval Process for TB Diagnostics

Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff

Medidée Services SA. Nano-Tera.ch. 05 February 2015 part 8. PMA, 510k, IDE. Pierre-Alain Sommer

US FDA: CMC Issues for INDs

FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond

An Introduction to the Worldwide Regulatory Framework for Medical Devices. Elizabeth Malo M.S., Director, Regulatory Affairs

Food and Drug Administration (FDA) 101

Combination Products at US FDA

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

A Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation

Pre-Clinical Testing for Devices and Diagnostics

FDA Regulation of In Vitro Diagnostics: Current Perspectives and Initiatives

Agenda. - Introduction Howard Birndorf. - ASR Issues and the Draft ASR FAQ Guidance Patrick Balthrop

Regulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC

Office for Human Subject Protection. University of Rochester

First Global Forum on Medical Devices Bangkok-Thailand, September Regulatory Control of Medical Devices in Tanzania

U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE. Jeff Shuren Director Center for Devices and Radiological Health

The In Vitro Diagnostic CRO

Research: Ethics, Informed Consent, FDA, Off Label Use

RE: Docket No. FDA 2017 N 0041: Agency Information Collection Activities; Proposed Collection; Comment Request; Safety Assurance Case

By: Clay Anselmo COO, DLLS, Founder Reglera and Terry J. Dagnon M.S., Vice President Regulatory Affairs, DLSS

Guidance for Industry and FDA Staff Procedures for Handling Post-Approval Studies Imposed by PMA Order

Validation of Laboratory-Developed Molecular Assays for Infectious Diseases

American Society of Cytopathology Core Curriculum in Molecular Biology

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

Software Regulation: The Transfusion Medicine Experience

FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies

FDA > CDRH > CFR Title 21 Database Search

How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab

FDA Regulation of Clinical Microbiology Diagnostic Devices

October 13, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Role of the WHO IVD Prequalification Programme in Light of National Regulatory Authority Approval

Standards and Regulatory Considerations for Orthopaedic Implants

was published. February 21, 2017

Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D

Molecular Diagnostics

Expanded Access and the Individual Patient IND

FDA Medical Device Industry Coalition. Medical Devices 101. An Educational Forum

FDA Perspective on Plasma Quality and GMPs

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS

Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics

MEMORANDUM. Re: Regulation of laboratory developed tests ( home brew assays) as medical devices ISSUES

Top 10. Changing Enforcement Environment. The Fourth Annual Medical Device Regulatory, Reimbursement and Compliance Congress November 10, 2009

What is an LDT? The Do s s And Don ts of Validating Laboratory Developed Tests

Tuesday, 21 October Jang Yong Choi

FDA's Initiative to Regulate Lab- Developed Tests (LDT) will Harm Patients and Academic Pathology

INVESTIGATIONAL DEVICE EXEMPTIONS AND EARLY FEASIBILITY STUDIES TO SUPPORT DEVICE INNOVATION

Guidance for Industry and FDA Staff. Replacement Reagent and Instrument Family Policy

FDA. Design of Biomedical Devices and Systems, 2nd Edition, King & Fries, CRC Press, 2009.

Agenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC

Murray Sheldon, MD Associate Director for Technology and Innovation Center for Devices and Radiological Health (CDRH) Office of the Center Director

The Long and Winding Road of Unique Device Identifier (UDI) Implementation: A Small Company Perspective

ASQ Tappan Zee Section Medical Devices, New Regulations and Standards. 26 th September / V. Fischer / Rev. 01

WCG ACADEMY COURSE OVERVIEW

Niccolo Machiavelli (1523)

Deciding When to Submit a 510(k) for a Change to an Existing Device Guidance for Industry and Food and Drug Administration Staff

Fourth Annual Pharmaceutical Regulatory and Compliance Congress

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: December 27, 2011

What is an Investigational Drug? 21CFR312.3(b)

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Medical Devices; Immunology and Microbiology Devices; Classification of the Nucleic Acid-

Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

CHARTING THE COURSE FOR PRECISION MEDICINE

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at

De Novo Classification Process (Evaluation of Automatic Class III Designation) Guidance for Industry and Food and Drug Administration Staff

Medical Devices; Immunology and Microbiology Devices; Classification of the Automated

Medical Device Development Tools. Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff

Regulatory Considerations and Trends Europe and the U.S.

Regulation of Microbiota- Based Products

Advertising and Marketing Genetic Tests New Pathways or Old Roads?

Global Clinical Trials in Korea

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

The Drug Development Process and Design of Clinical Trials

About Clinical Trials

State of the Clinical Trials Industry

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

FDA Overview of the Process for Clearance and Approval of Mass Spectrometry-based In vitro Diagnostic Devices

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

Combination Products: A 40 Year Regulatory Evolution

Introduction to Clinical Research

The GS1 System and services (GTIN, GLN and GDSN) can be used to comply with this rule.

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Food Safety Modernization Act (FSMA) & Imports of Food Products. August 9 th, 2016 Russell Statman, Registrar Corp

Korean Medical Devices Regulations

4. 510(k) Summary K to g

FAQ ABOUT. 21CFR Part 1271 FDA REGULATION OF REPRODUCTIVE TISSUE LABS

FDA Update on Compounding

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

FDA FSMA Timeline. July 29, 2009 House version passed. Nov. 30, 2010 Senate version passed. Dec. 19, 2010 Senate revised version passed

Life Sciences Online Courses

Voluntary Pilot Meeting Preview: How will CDRH apply assessments in the voluntary program?

Human Research Protection Program Guidance for Human Research Determination

Transcription:

Molecular Diagnostics: The Shift to Complexity Molecular Diagnostics Regulation: Where do we go from here? David W Feigal, Jr., MD MPH April 17, 2015

Oversight of In Vitro Diagnostics States Center for Devices and Radiological Health Medical Devices Health Professionals IRB s Health Facilities Clinical Laboratories Improvement Amendments (CLIA) Program

Is this an FDA regulated Device?

Is this an FDA regulated drug?

FDA Authority FDA Definition of a Device Instrument, apparatus, implement, machine, contrivance, implant, in Vitro reagent, or other similar or related article, including any component, part, or accessory, which is - intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and

CLIA Authorities Laboratory or clinical laboratory defined: As used in this section, the term laboratory or clinical laboratory means a facility for the biological, microbiological, serological, chemical, immuno-hematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.

FDA and CLIA It isn t either / or In clinical medicine it is always both

Medical Device Approval Process

Historical Overview of Devices 1906 1937 No FDA Authority 1938 1976 1976 No Pre-market Authority but could take action for devices on the market Some products reviewed as drugs : NDA-devices (sutures, implants ) Risk stratified requirements Premarket approval for some devices

Device Regulatory Path Class I Pre Amendment Marketed Devices Class II New Products: Risk-based Regulation Grandfathered No further review to stay on the market 1976 Class III Classified into risk groups by FDA and Advisory Committees

Device Regulation Class I & II Exempt Class I & II Non Exempt Class III Not Regulate d Regulator y Discretion LDTs Registe r & List MDR Informed Consent IDE (Sig Risk) + + + + 510(k) PMA + + + + + + + + + + + +??? no no? Usually no

Investigational Use IDE* May be required for medical device clinical trials, usually for Class III products If the study presents non-significant risk then an FDA IDE application is not needed Whether IDE or not must follow Good Clinical Practices Protocol & record keeping Qualified investigators IRB approval Informed consent * Very similar requirements to an IND for Drugs or Biologics

Medical Device Quality Systems (QSR) Why approach medical devices differently than drugs and biologics? Do the CLIA standards replace QS?

CDRH and Standards Development Standards Recognition Process Candidate standards reviewed by multidisciplinary team; FR Notice published when standards are recognized Examples: ASTM F04.93: ISO/TC150/SC3/ISO FDIS 9713: Neurosurgical Implants - Self-Closing Intracranial Aneurysm Clips ANSI/AAMI/ISO TC 194, 10993-6:1995: Biological Evaluation of Medical Devices - Part 6: Tests for Local Effects After Implantation (Reaffirmation, Revision or Withdrawl) IEC TC 62/SC 62A/: 62A/XXX/NP: New Work Item: Medical Device Software - Software Life Cycle Processes ASTM F04.21: Revision of F1350-91(2000) Standard Specification Wrought 18 Chromium-14 Nickel-2.5 Molybdenum Stainless Steel Surgical Fixation Wire (UNS S31673)(Main Committee Ballot F040101, Item#24)

How FDA has Dealt with New Technology 1902 Biologics Existing vaccine and toxin manufactures had to be licensed and inspected annually Nothing grandfathered Half of the companies shut down

How FDA has Dealt with New Technology 1906 Pure Food and Drugs Act Labels not misbranded, products not adulterated Nothing grandfathered Burden on FDA to prove violations

How FDA has Dealt with New Technology 1938 Food Drug & Cosmetic Act New Drug Applications Existing drugs grandfathered 1962 Kefauver Amendments New Drug Applications Pre-1938 Drugs grandfathered Tens of thousands drugs removed from the market through the DESI Review Process

Is this an FDA regulated drug?

How FDA has Dealt with New Technology 1969 Bactodisk Supreme Court Decision Finding: Diagnostics are Drugs FDA Responds by not requiring NDAs but with labeling standards 1976 Device Amendments Pre-1976 devices grandfathered Devices classified Call for PMAs for class III removes many products from the market

How FDA has Dealt with New Technology Voluntary Efforts that Failed: Meat packing inspectors Advertising standards Animal Research standards Clinical Research Standards Mamography Quality Postmarketing Study Comittments

IVD and Disease Linked Cycles CDC NIH IVD Manufacturers Research Labs Clinical Labs CDC WHO Public Health Networks FDA CLIA

Are LDT s all Potti Trained?

Diagnostics: Need to be Fit for Use Regulatory Requirements: (the consumer protections) Need to be Fit for Purpose

Personal Recommendations Risk Diagnostic Regulation Integrate CLIA standards with Quality Systems Standards based lab processes (CLIA) General purpose lab equipment (FDA) Good Clinical Practices / Recalls add to CLIA oversight Class III diagnostics Always regulated by FDA LDT or not Class II Diagnostics Novel: FDA regulated to set standards. Once standards set: 510(k) exempt Analytes standards needed